Silicone comeback looking grim

WASHINGTON – Staffers at the Food and Drug Administration have scrutinized Inamed and Mentor’s bid to get silicone breast implants back on the U.S. market. While no final ruling has been made, studies by the two medical device companies presented to the FDA were said to have “limited value” because they did not address implant rupture rate or health effects due to ruptured implants. Arizona-based device company Medicis plans to acquire Inamed for $2.8 billion (see Aesthetic Medicine Makeover). Inamed shares fell $1.30 to $64.93 in recent trading. Mentor shares rose $1.00 to $32.90 in recent trading.